Introduction
It is estimated that at the end of 2008, approximately 33.2 million people were infected worldwide with human immunodeficiency virus (HIV a ), the etiologic cause of acquired immunodeficiency syndrome (AIDS). Each year, around 2.7 million more people become infected with HIV and 2 million die of AIDS. 1 Considering that the development of a safe and effective HIV vaccine is still in the future, 2 the current research continues to focus on the disease treatment by chemical anti-HIV agents. Although significant progress has been made since the introduction of highly active antiretroviral therapy (HAART), 3, 4 which employs a combinational use of nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and/or protease inhibitors (PIs), it has also led to some serious problems, including increased adverse effects and the emergence of multidrugresistant viral strains. [5] [6] [7] Drug-resistant virus is then involved in HIV transmission, and more than 25% of newly infected individuals harbor HIV-1 isolates that are resistant to at least one ART. 8 Therefore, novel potent antiretroviral agents with different targets than currently approved drugs may hold particular promise in addressing issues of current therapies.
Our prior modification study on betulinic acid (BA, 1) resulted in the discovery of bevirimat [3-O-(3 0 ,3 0 -dimethylsuccinyl)-betulinic acid, 2]. 9 Bevirimat exhibits extremely potent antiviral activity against HIV-1 primary isolates and several drug-resistant viruses and represents a unique first in a class of anti-HIV compounds termed maturation inhibitors (MIs). 10, 11 MIs block the last step of viral Gag precursor polyprotein processing from p25 (CA-SP1) to functional p24 (CA), resulting in the production of noninfectious immature HIV-1 particles. Most importantly, MIs retain their high anti-HIV potency against different viral strains that are resistant to current ARTs, including AZT (NRTI), Nevirapine (NNRTI), and Indinavir (PI). Compound 2 has recently succeeded in phase IIb clinical trials and is in preparation for phase III clinical trials. [12] [13] [14] To summarize our prior structure-activity relationship (SAR) study of 2 and other 3-O-acyl-BA derivatives, we know that C-3 ester substitution is important to the enhanced antiviral activity. 9, 15 Within the C-3 side chain, the proper length, a terminal carboxylic acid, and C-3 0 dimethyl substitution contribute to antiviral potency. However, the C-3 ester groups of prior BA analogues have mainly contained freely rotatable alkyl chains. Therefore, in the present study, five C-3 conformationally restricted BA analogues (4) (5) (6) (7) (8) were synthesized in order to explore the conformational space of the C-3 pharmacophore. Two 3-O-monomethylsuccinyl betulinic acid (MSB) derivatives (9-10) and compound 11 were further designed to investigate how the methyl substituents on the C-3 side chain impact the antiviral potency.
Meanwhile, moronic acid (MA, 3), which was isolated from Brazilian propolis, also exhibited promising anti-HIV activity as a lead compound with an EC 50 of 0.1 μg/mL. 16 a Abbreviations: AIDS, acquired immunodeficiency syndrome; HIV-1, human immunodeficiency virus type 1; BA, betulinic acid; MA, moronic acid; HAART, highly active antiretroviral therapy; NRTI, nucleoside/ nucleotide reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; MI, maturation inhibitor; P24 (CA), capsid; P25 (CA-SP1), capsid precursor; Bevirimat, 3-O-(3 0 ,3 0 -dimethylsuccinyl)-betulinic acid; MSB, 3-O-monomethylsuccinyl betulinic acid; EDCI, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride; DMAP, 4-(dimethylamino)pyridine; TBDPS, tert-butyldimethylsilyl; TBAF, tetra-n-butylammonium fluoride; THF, tetrahydrofuran; TEM-PO, 2,2,6,6-tetramethyl-1-piperidinyloxy; PhI(OAc) 2 , (diacetoxyiodo) benzene; NaBH 4 , sodium borohydride; Et 3 N, triethylamine; TFAA, trifluoroacetic anhydride; AZT, zidovudine; PI, postinfection. in 2 at the 3β position of morolic acid (30), the C-3 ketone reduced analogue of 3, unexpectedly did not increase the antiviral activity. 16 Because 2 and 30 share similar 3D conformational space of their triterpene skeletons, this unexpected result led us to further investigate possible modifications on analogues of 3 and 30.
Detailed SAR of triterpene-derived HIV-1 maturation inhibitors has been established from the current study. This analysis led to the design and synthesis of compound 12 with slightly better activity than 2.
Design. Because the presence of C-3 substitution is critical to the anti-HIV-1 activity of BA derivatives, five conformationally restricted 3-O-acyl-BA analogues (4-8) ( Figure 1 ) were first synthesized and evaluated in order to further explore the conformational space of this pharmacophore. The C-3 0 dimethyl group was also moved toward the 4 0 -position in a C-3 glutaryl-substituted compound (11) (Figure 1 ) to study the influence of different positioning of the methyl groups. In addition, although we know that the presence of the C-3 0 dimethyl within the C-3 side chain is vital to anti-HIV-1 activity, it is still unclear which, if either, C-3 0 methyl group of 2 contributes more toward activity. Therefore, 3-O-monomethylsuccinyl betulinic acid (MSB) derivatives (9-10) ( Figure 1 ) were designed and synthesized. 17 Their antiviral activities were then evaluated in vitro against HIV-1 IIIB replication in MT-2 cell lines. Diverse substitutions (13-21) (Scheme 4) were also incorporated into 30 to study their influence on the antiviral potency and the impact of the triterpene skeleton itself on the antiviral activity. After reviewing the initial promising bioassay results, compound 12 ( Figure 1 ) was then designed to try to improve the antiviral potency of 2.
Chemistry
Compounds 4 and 5 were synthesized by reaction of the corresponding cycloalkanedicarboxylic acid with the C-3 β-hydroxyl group of 1 in the presence of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDCI) and dimethylaminopyridine (DMAP), resulting in yields of 26% and 35%, respectively (Scheme 1). Compounds 6-8 and 11 were synthesized according to Scheme 2. Reaction of the corresponding acid anhydride with 1 furnished the target compounds in yields of 35-55%.
The synthesis of MSB analogues was reported before in ref 17 . As shown in Scheme 3, the hydroxyl of 3R-bromo-2-methylpropanol (22a) was first protected by a tert-butyldimethylsilyl (TBDPS) moiety to yield 23a quantitatively. The bromide group was then replaced with a cyano moiety (24a), which was reduced to an aldehyde moiety (25a) 18 and consequentially oxidized to a carboxylic acid (26a). Reaction of 1 with 26a led to esterification of the 3β-hydroxy group of 1 to provide 27a. After cleavage of the TBDPS group with TBAF in THF, the primary hydroxyl of 28 was oxidized to a carboxylic acid in the presence of 2,2,6,6-tetramethyl-1-piperidinyloxy (TEMPO) and PhI(OAc) 2 to give 3-O-(3 0 Rmethylsuccinyl)-betulinic acid (3 0 R-MSB, 9). 19 The 3 0 S-MSB isomer (10) was synthesized using the same method starting with 3S-bromo-2-methylpropanol (22b).
Scheme 4 depicts the synthesis of MA analogues. Compound 3 was first treated with NaBH 4 to yield 3β-hydroxyl group of 30. Different acyl chloride was then reacted with 30 in the presence of Et 3 N to furnish 3-O-acyl-MA analogues 13-21.
The synthesis of 12 started from the commercially available 2-ethyl-2-methylsuccinic acid (31), which was stirred in trifluoroacetic anhydride (TFAA) to form 2-ethyl-2-methylsuccinic anhydride (32). The reaction of 32 with 1 furnished 3-O-(3 0 -ethyl-3 0 -methylsuccinyl) betulinic acid (12) in 55% yield (Scheme 5).
Results and Discussion
The newly synthesized conformationally restricted 3-Oacyl-BA analogues (4) (5) (6) (7) (8) were first tested in acutely HIV-1 IIIB infected MT-2 cell lines and compared to 2 and AZT. The data are listed in Table 1 . Only the 2-methylmaleic acid substituted BA derivative (8) showed moderate anti-HIV-1 activity, with a TI of 1.4 Â 10 2 and an EC 50 of 0.18 μM. A pendant cyclopentyl or cyclohexyl ring within the C-3 side chain reduced the antiviral potency of the derivatives (4-7) significantly. One possible reason for the reduced or abolished activity of these compounds is that the pendant ring moieties are locked into a conformation that is not the bioactive one. Alternatively, steric hindrance at the 2 0 -position [as was seen with 3-O-(2 0 ,2 0 -dimethylsuccinyl) BA, which had an EC 50 of only 2.7 μM] 9 may be a contributing factor to the loss in potency. This hindrance may impart an unfavorable interaction with either the binding site, resulting in reduced affinity, or the triterpene template, leading to an unfavorable C-3 side chain conformation.
In contrast, 3-O-(4 0 ,4 0 -dimethylglutaryl)-betulinic acid (11) had an antiviral EC 50 of 0.048 μM and a TI of 8.7 Â 10 2 . This result confirms that the dimethyl moiety is essential to the anti-HIV-1 potency of 3-O-acyl-BA analogues. Although moving the dimethyl substitution to the 2 0 -position was highly detrimental, moving the dimethyl group to the 4 0 -position of the C-3 side chain was well tolerated and significantly increased the antiviral activity compared with that of the unesterified compound 1. However, the anti-HIV-1 activity of 11 was still 20-fold less than that of 2, indicating that the 3 0 -position, rather than 4 0 -position, of the C-3 side chain remains the optimal substitution position. Overall, results of the conformationally restricted compounds (4-8) and 11 stimulated our interest in further study of the importance of the C-3 0 dimethyl moiety and the exact contribution of both groups to the anti-HIV-1 potency of 2.
The MSB analogues 9 and 10 were then synthesized and evaluated in parallel with 2 and AZT against viral replication in HIV-1 IIIB infected MT-2 cell lines. A 1:1 mixture (33) of 9 and 10 was also tested. The anti-HIV-1 activity data of these derivatives are also listed in Table 1 . Among the MSB derivatives, compound 10 with 3 0 S-methyl showed very potent antiviral activity with a TI of 3.8 Â 10 3 and EC 50 of 0.0087 μM, which is comparable to that of 2 (EC 50 : 0.0013 μM). Compound 9 with 3 0 R-methyl exhibited only moderate anti-HIV-1 activity with a TI of 3.7 Â 10 2 and EC 50 of 0.12 μM. The antiviral activity (EC 50 : 0.016 μM) of the mixture (33) of the two stereoisomers fell in between those of 9 and 10. This result indicates that the two C-3 0 methyl groups in the C-3 ester side chain contribute differently to the extremely potent anti-HIV-1 activity of this compound class. We postulate that interaction of the 3 0 S-methyl group with the viral target might be essential to the anti-HIV-1 activity of 2. The interaction of 0 R-methyl group within the target is less significant but still necessary because 2, with dimethyl substitution at C-3 0 position, is slightly more potent than 10.
To further elucidate the mechanism of action, the production of virus from 10-treated HIV-1 wild-type (NL4-3) or resistant variants transfected HeLa cells were subjected to characterization. Radioimmunoprecipitation analyses revealed that, like 2, 10 also functions as a maturation inhibitor. In detail, 10 specifically inhibited the conversion of p25 (CA-SP1) to p24 (CA) in both cell and virion lysates ( Figure 3 showing the results from virion lysate), which led to defective Gag processing and production of morphologically abnormal, noninfectious virion particles.
The anti-HIV replication activity of newly synthesized MA analogues 13-21 were tested against HIV-1 IIIB and summarized in Table 1 as well. These compounds have diverse substitutions at the 3β position of analogue 30 to explore the conformational space to enhance the antiviral potency. However, none of them showed significant anti-HIV activity. Nevertheless, although the insertion of the 3 0 ,3 0 -dimethylsuccinyl side chain into the 3β of 30 did not follow the general trend of increasing the activity, the current study indicates that a terminal polar moiety, such as a carboxylic acid group, may still be necessary for the compounds to exert their antiviral replication activity. It also proves that the triterpene skeleton itself plays an important role in the enhanced anti-HIV activity of BA derivatives. As stated above, our investigation of the C-3 0 chiral center of the anti-HIV-1 clinical trials agent 2 showed that the 3 0 S-methyl group is the major contributor to enhanced anti-HIV-1 activity, while the 3 0 R-methyl group is less important but still necessary. Accordingly, we postulated that the latter effect may be due to insufficient interaction or a slightly different positioning of the 3 0 S or 3 0 R moiety. To confirm our hypothesis, one of the methyl groups was further enlarged to an ethyl group to give the 3 0 -ethyl-3 0 -methyl substitution found in 12, which is a mixture of 3 0 R and 3 0 S isomers. Compound 12 was evaluated and compared with 2 and AZT in a HIV-1 IIIB infected MT-2 cell line. It showed very potent antiviral activity with an EC 50 of 0.0006 μM and TI of 6.1 Â 10 4 , which was more active than 33, the mixture of 9 and 10. Indeed, its potency was slightly better than those of 10 and 2.
To identify which isomer is the active component, the two C-3 0 diastereoisomers (12a and 12b) of 12 were separated by using recycling preparative HPLC (JAI LC-918). After four cycles of separation, the two isomers were obtained successfully (Figure 2) . Their purities were ascertained by analytical HPLC. By comparing the 1 H NMR spectra and the optical rotation data of 2, 9, 10, 12a, and 12b, we assigned 12a as the 3 0 S isomer and 12b as the 3 0 R isomer. The antiviral activities of 12a and 12b were determined in HIV-1 NL4-3 infected MT-4 lymphocytes, where 12a was active and 12b showed no antiviral activity. This result indicates that within the C-3 pharmacophore of BA-derived maturation inhibitors, the 3 0 S substitution is critical to the anti-HIV activity. Modification on this site may further increase the antiviral potency of the current maturation inhibitors.
To conclude our SAR investigation of the C-3 modification on triterpene-derived anti-HIV agents, we found that no conformationally restricted 3-O-acyl BA analogue (4) (5) (6) (7) (8) showed significant antiviral activity, indicating that C-3 0 dimethyl substitution of the succinyl side chain is crucial to the high potency of 2. A C-3 terminal polar moiety, such as carboxylic acid, is also very important to the antiviral activity, as was proven by MA analogues 13-21. Further SAR study of the C-3 0 chiral center of the newly designed MSB analogues (9-10) revealed that the 3 0 S-methyl group of 2 is the major contributor to the compound's enhanced anti-HIV-1 activity. This result led us to design and synthesize compound 12, which has an enlarged C-3 0 substituent (methylethyl instead of dimethyl). As we anticipated, 12 showed extremely potent antiviral activity and was slightly better than 2. Further investigation confirmed that 12a, the 3 0 S isomer, is the active compound. This result provides us with better SAR information to further design the next generation of potent BA derived HIV-1 maturation inhibitors.
Experimental Section
Chemistry. The melting points were measured with a Fisher Johns melting apparatus without correction. 
Synthesis of BA Derivatives 4 and 5.
A solution of 1 (1 equiv), EDCI (8 equiv), DMAP (2 equiv), and the proper cycloalkanedicarboxylic acid (5 equiv) in anhydrous CH 2 Cl 2 (8 mL) was stirred at rt overnight until the starting material was not observed by TLC. The solution was diluted with CH 2 Cl 2 (20 mL) and washed three times with brine and distilled water. The organic layer was dried over anhydrous Na 2 SO 4 and concentrated to dryness under reduced pressure. The residue was chromatographed using a silica gel column to yield the pure target compounds. Synthesis of BA Derivatives 6-8 and 11. A solution of 1 (1 equiv), DMAP (2 equiv), and the proper acid anhydride (5 equiv) in anhydrous pyridine (1.5 mL) was stirred at 160°C for 2 h using microwave. The reaction mixture was diluted with EtOAc (20 mL) and washed three times with 20% HCl solution and distilled water. The organic layer was dried over anhydrous Na 2 SO 4 and concentrated to dryness under reduced pressure. The residue was chromatographed using a silica gel column to yield the pure target compounds.
3β-O-(3 0 -Carboxycyclohex-5 0 -enecarbonyl)-betulinic Acid (6). Yield 40% (starting with 100 mg of 1); white amorphous powder; mp 178-180°C. MS (ESI-) m/z: 607. 4 1 equiv) , and TBDPSCl (1.1 equiv) in dry DMF was stirred at rt until the starting material was not observed by TLC. The reaction mixture was diluted with EtOAc and washed with 20% HCl solution and distilled water. The organic layer was dried over anhydrous Na 2 SO 4 and concentrated to dryness under reduced pressure. The residue was chromatographed using a silica gel column to yield the pure target compounds.
(3R-Bromo-2-methylpropoxy)(tert-butyl)diphenylsilane (23a). Yield 2.03 g (100%) from 22a; colorless oil. MS (ESIþ) m/z:
BrOSi. (3S-Bromo-2-methylpropoxy)(tert-butyl)diphenylsilane (23b). Yield 1.44 g (100%) from 22b; colorless oil. MS (ESIþ) m/z:
BrOSi. Synthesis of 24a and 24b. To a solution of 23a or 23b (1 equiv) in dry DMSO (10 mL) was added sodium cyanide (3 equiv). The mixture was stirred at 120°C for 2 h until the starting material was not observed. After cooling to rt, the reaction was diluted with diethyl ether (30 mL) and washed with distilled water. The organic layer was dried over anhydrous Na 2 SO 4 and concentrated to dryness under reduced pressure. The residue was chromatographed using a silica gel column to yield the pure target compounds.
4-(tert-Butyldiphenylsilyloxy)-3R-methylbutanenitrile (24a). Yield 1.70 g (93%) starting with 23a; colorless oil.
NOSi. Synthesis of 25a and 25b. To a solution of 24a or 24b (1 equiv) in anhydrous toluene (10 mL) was added diisobutylaluminium hydride (DIBALH, 1.1 equiv) dropwise at 0°C under argon. After stirring for 30 min, ice water was added slowly followed by 10% HCl and aqueous saturated potassium tartrate. Stirring was continued for 15 min at 0°C, and then the aqueous layer was extracted three times with CH 2 Cl 2 . The organic layer was dried over anhydrous Na 2 SO 4 and concentrated to dryness under reduced pressure. The residue was chromatographed using a silica gel column to yield the pure target compounds.
4-(tert-Butyldiphenylsilyloxy)-3R-methylbutanal (25a). Yield 1.02 g (95%) starting with 24a; colorless oil. MS (ESIþ) m/z:
Si. Synthesis of 26a and 26b. To a solution of 25a or 25b (1 equiv) in dry DMSO (1.0 mL) was added NaH 2 PO 4 3 H 2 O (0.8 equiv in 2.0 mL H 2 O) and 80% NaClO 2 (1.5 equiv in 2.0 mL of H 2 O) dropwise over 5 min. The mixture was stirred overnight. The reaction was quenched with saturated NH 4 Cl solution and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na 2 SO 4 , and concentrated to dryness under reduced pressure. The residue was chromatographed using a silica gel column to yield the pure target compounds.
4-(tert-Butyldiphenylsilyloxy)-3R-methylbutanoic Acid (26a 3 -23, 24, 25, 26, 27) .
Synthesis of 28 and 29. A solution of 27a or 27b (1 equiv) and TBAF (1.0 M in THF, 3 equiv) in anhydrous THF was stirred at 0°C for 1.5 h. The mixture was then allowed to warm to rt and stirred until there was no starting material detected by TLC. The reaction was diluted with 15 mL of CH 2 Cl 2 and washed with saturated NH 4 Cl solution and brine. The organic layer was dried over anhydrous Na 2 SO 4 and concentrated to dryness under reduced pressure. The residue was chromatographed using a silica gel column to yield the pure target compounds. 2 (1.5 equiv). The mixture was stirred at rt until the starting material was not observed by TLC. The reaction was filtered through thin silica gel pad and eluted with CH 2 Cl 2 and washed with saturated NH 4 Cl solution and brine. The organic layer was dried over anhydrous Na 2 SO 4 and concentrated to dryness under reduced pressure. The residue was chromatographed using a silica gel column to yield the pure target compounds. m, H-13), 1.69 (3H, s, H-30), 1.28, 1.26 (3H, d, 2-Ethyl-2-methylsuccinic acid (50 mg, 4 equiv) was stirred in TFAA at rt for 3 h until the reaction mixture became homogeneous. The solution was then concentrated to dryness under reduced pressure to yield 2-ethyl-2-methylsuccinic anhydride (32). Compound 32 was reacted without further purification with 1 (36 mg, 1 equiv) and DMAP (19 mg, 2 equiv) in anhydrous pyridine (1.5 mL), stirring at 160°C for 2 h in microwave. The reaction mixture was diluted with EtOAc (10 mL) and washed three times with 20% HCl solution and distilled water. The organic layer was dried over anhydrous Na 2 SO 4 and concentrated to dryness under reduced pressure. The residue was chromatographed using a silica gel column to yield 30 mg (55%) of 12; white amorphous powder.
3β-O-(3 0 S-Ethylmethylsuccinyl)-betulinic Acid (12a Synthesis of MA Derivatives 13-21. To a solution of 30 in dry CH 2 Cl 2 were added triethylamine (50 μL) and corresponding acyl chloride (50 μL). The reaction was stirred at rt for 30 min. The mixture was diluted with CH 2 Cl 2 and washed with 10% HCl. The organic layer was dried over anhydrous Na 2 SO 4 and concentrated to dryness under reduced pressure. The residue was chromatographed using a silica gel column to yield the pure target compounds. 
